Progress of targeted therapy for primary central nervous system lymphoma
10.3760/cma.j.cn115356-20210525-00127
- VernacularTitle:原发性中枢神经系统淋巴瘤新靶向治疗研究进展
- Author:
Xin WAN
1
;
Ou BAI
Author Information
1. 吉林大学第一医院血液科，长春 130021
- Keywords:
Central nervous system neoplasms;
Lymphoma;
Immunosuppressive agents;
Molecular targeted therapy
- From:
Journal of Leukemia & Lymphoma
2022;31(3):182-185
- CountryChina
- Language:Chinese
-
Abstract:
Primary central nervous system lymphoma (PCNSL) is a rare invasive non-Hodgkin lymphoma. Although high dose methotrexate-based induced chemotherapy regimen has significantly improved prognosis of patients, 30 percent -40 percent of patients still relapse with poor prognosis. With the development of molecular biology, new targeted drugs like cell signaling pathway kinase inhibitors have become new treatment options for PCNSL.
